{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:01:52Z","timestamp":1791561712469,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen Pharma SAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.esmoop.2025.105534","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T13:14:30Z","timestamp":1754399670000},"page":"105534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial"],"prefix":"10.1016","volume":"10","author":[{"given":"D.","family":"Melisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Macarulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"De La Fouchardi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Pazo Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.R.","family":"Chandana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.O.","family":"Goetze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Paulson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Hubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Benzaghou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.A.","family":"Wainberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2025.105534_bib1","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/ijc.33336","volume":"148","author":"Al-Batran","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2025.105534_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmoop.2025.105534_bib3","article-title":"SEER\u2217Explorer: an interactive website for SEER cancer statistics. Data source(s): SEER Incidence Data, November 2023 Submission (1975-2021), SEER 22 registries (excluding Illinois and Massachusetts)","year":"2024","journal-title":"Expected survival life tables by socio-economic standards"},{"key":"10.1016\/j.esmoop.2025.105534_bib4","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2217\/fon-2020-0749","article-title":"Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer","volume":"17","author":"Carrato","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.esmoop.2025.105534_bib5","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.2147\/CMAR.S376261","article-title":"Health-related quality of life of patients with metastatic pancreatic cancer: a systematic literature review","volume":"14","author":"Yoo","year":"2022","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.esmoop.2025.105534_bib6","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/MPA.0000000000001025","article-title":"Quality of life in patients with pancreatic cancer and their caregivers: a systematic review","volume":"47","author":"Bauer","year":"2018","journal-title":"Pancreas"},{"key":"10.1016\/j.esmoop.2025.105534_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1200\/JCO.2018.36.4_suppl.335","article-title":"Deposition characteristics and resulting DNA damage patterns of liposomal irinotecan (nal-IRI) in pancreatic cancer xenografts","volume":"36","author":"Leonard","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105534_bib9","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/0008-5472.CAN-05-4007","article-title":"Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy","volume":"66","author":"Drummond","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105534_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40487-022-00215-2","article-title":"Liposomal irinotecan shows a larger therapeutic index than non-liposomal irinotecan in patient-derived xenograft models of pancreatic cancer","volume":"11","author":"Barbier","year":"2023","journal-title":"Oncol Ther"},{"key":"10.1016\/j.esmoop.2025.105534_bib11","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2025.105534_bib12","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1200\/JCO.2024.42.16_suppl.4136","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-na\u00efve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): updated overall survival analysis with 29-month follow-up of NAPOLI 3","volume":"42","author":"Hussein","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105534_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113430","article-title":"Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: the open-label, multicenter, phase II nITRO trial","volume":"196","author":"Melisi","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2025.105534_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241234487","article-title":"Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear","volume":"16","author":"Melisi","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.esmoop.2025.105534_bib17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2025.105534_bib18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105534_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2023.04.027","article-title":"Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: a synthesis across 21 clinical trials involving nine different cancer types","volume":"188","author":"Musoro","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2025.105534_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","article-title":"General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States","volume":"107","author":"Nolte","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2025.105534_bib21","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3390\/cancers16071323","article-title":"Results of a randomized, double-blind, placebo-controlled, phase 1b\/2 trial of nabpaclitaxel + gemcitabine \u00b1 olaratumab in treatment-na\u00efve participants with metastatic pancreatic cancer","volume":"16","author":"Gardner","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2025.105534_bib22","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/s41416-020-0846-2","article-title":"Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma","volume":"122","author":"Corrie","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2025.105534_bib23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2018.09.029","article-title":"Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin","volume":"106","author":"Hubner","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2025.105534_bib24","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.105534_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50756","article-title":"NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: a systematic review and meta-analysis","volume":"7","author":"Nichetti","year":"2024","journal-title":"JAMA Netw Open"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T21:14:29Z","timestamp":1759612469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925014036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2059702925014036"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105534","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105534"}}